NCT03409614 · OUTCOME

Part 2: DoR

Combinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-based Doublet Chemotherapy in Patients With Lung Cancer · Source last updated 2026-05-18

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: MEDIAN
Unit: months
Interval / dispersion: 95% Confidence Interval
Time frame: Up to 32 months

What was measured

DoR was defined as the time from date of first documented response of CR or PR to the date of first documented PD or death due to any cause, whichever occurred earlier.

Analysis population: Part 2 participants with confirmed CR or PR only. Overall number of participants analyzed = number of participants with evaluable data for the outcome measure

Groups in this outcome

Part 2: Cemiplimab + Chemotherapy

Participants received cemiplimab plus platinum-based doublet chemotherapy

Part 2: Placebo + Chemotherapy

Placebo matching cemiplimab plus platinum-based doublet chemotherapy

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Part 2: Cemiplimab + Chemotherapy	136
Part 2: Placebo + Chemotherapy	34

Reported measurements

Source class 1

Values in months · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Part 2: Cemiplimab + Chemotherapy	16.4	Not reported	13.1	19.5	Not reported
Part 2: Placebo + Chemotherapy	7.3	Not reported	4.2	11.3	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
lower Limit
13.1
upper Limit
19.5
value
16.4
group Id
OG001
lower Limit
4.2
upper Limit
11.3
value
7.3

denoms

counts
group Id
OG000
value
136
group Id
OG001
value
34
units
Participants

description

DoR was defined as the time from date of first documented response of CR or PR to the date of first documented PD or death due to any cause, whichever occurred earlier.

dispersion Type

95% Confidence Interval

groups

description
Participants received cemiplimab plus platinum-based doublet chemotherapy
id
OG000
title
Part 2: Cemiplimab + Chemotherapy
description
Placebo matching cemiplimab plus platinum-based doublet chemotherapy
id
OG001
title
Part 2: Placebo + Chemotherapy

param Type

MEDIAN

population Description

Part 2 participants with confirmed CR or PR only. Overall number of participants analyzed = number of participants with evaluable data for the outcome measure

reporting Status

POSTED

time Frame

Up to 32 months

title

Part 2: DoR

type

SECONDARY

unit Of Measure

months

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice